中文

Krystal (KRYS)

Biotech

Close on Nov 2, 2026 (from our latest article): $295.90

Market value
$8.8Bat the Nov 2 close
Revenue growth
+26%12 months to Sep 30, 2026 (10-Q)
FCF margin
66%12 months to Sep 30, 2026 (10-Q)
Net cash
$1.2Bat Sep 30, 2026
Worst fall since listing
−53.4%Mar 1, 2021 to Nov 26, 2021; back to that high in Nov 2021

About the company

Latest

  • Down 11% Move
    Krystal Biotech falls 11% as pipeline delays overshadow a beat

The Long View

Krystal spent its first seven years developing Vyjuvek, funded by share sales, then turned profitable within a year of its 2023 approval.

Self-funding

▲ better · ▼ worse · ⚠ watch, latest quarter · share count · cash

Updated Nov 2, 2026

Read the Long View →

Our View Opinion

Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.

No Our View yet. Request one →

More of our coverage that names Krystal

Long-term fundamentals

Annual results for Krystal, FY2016–FY2025, as reported in its 10-K filings.

Revenue and free cash flow

Revenue went from $51M in FY2023 to $389M in FY2025. Free cash flow was positive in 2 of the 10 years shown; FY2025: $189M. Each year's figures are in the table below. −$200M$0$200M$400M ’16 ’17 ’18 ’19 ’20 ’21 ’22 ’23 ’24 ’25

Revenue went from $51M in FY2023 to $389M in FY2025.

Free cash flow was positive in 2 of the 10 years shown; FY2025: $189M.

Margins

Operating margin was 41% in FY2025, vs −216% in FY2023. Each year's figures are in the table below. −300%−200%−100%0%100% ’23’24’25

Operating margin was 41% in FY2025, vs −216% in FY2023.

Diluted share count

The diluted share count rose 59% from FY2020 to FY2025, to 30M. Each year's figures are in the table below. 17.5M20M22.5M25M27.5M30M ’20’21’22’23’24’25

The diluted share count rose 59% from FY2020 to FY2025, to 30M.

Results and cash flow

Fiscal yearRevenueGross marginOperating marginNet incomeOperating cash flowCapital spendingFree cash flow
FY2025$389M—41%$205M$201M$12M$189M
FY2024$291M—23%$89M$123M$4M$119M
FY2023$51M—−216%$11M−$89M$12M−$101M
FY2022$0——−$140M−$101M$53M−$154M
FY2021$0——−$70M−$48M$68M−$116M
FY2020———−$32M−$26M$15M−$41M
FY2019———−$19M−$19M$6M−$25M
FY2018———−$11M−$9M$2M−$12M
FY2017———−$8M−$4M$0.2M−$4M
FY2016———−$1M−$1M$0.0M−$1M

Shares, cash, debt and payouts

Fiscal yearDiluted sharesCash and investmentsDebtStock-based payDividends paidBuybacks
FY202530M$956M—$55M——
FY202430M$750M—$49M——
FY202328M$594M—$40M——
FY202225M$384M—$33M——
FY202122M$502M—$15M——
FY202019M$271M—$3M——
FY2019—$194M—$1M——
FY2018—$112M—$0.8M——
FY2017—$50M—$0.2M——
FY2016—$2M$2M$0.0M——

Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 2, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.

Returns by year

YearKRYSS&P 500
2019+166.5%+31.5%
2020+8.3%+18.4%
2021+16.6%+28.7%
2022+13.3%−18.1%
2023+56.6%+26.3%
2024+26.3%+25.0%
2025+57.4%+17.9%
2026 to date+28.1%+5.9%

Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.

Other companies we cover in Biotech

Show all 17

Questions about Krystal

How does Krystal Biotech make money?
Almost entirely from one product, Vyjuvek, a gene therapy gel applied to the wounds of people with dystrophic epidermolysis bullosa (DEB), a rare genetic skin disease. Vyjuvek brought in $470 million of revenue in the 12 months to September 2026; Krystal has no other approved product. More in the Long View →
Where is Krystal's growth coming from?
Outside the US. In the first nine months of 2026, US Vyjuvek sales were about 1% lower than a year earlier, while sales in Europe and Japan, where Vyjuvek launched in late 2025, made up about a quarter of revenue. Krystal is also testing the same gene-delivery technology in eye, lung, skin and cancer programs. More in the Long View →
What could slow Krystal's growth?
Its dependence on a single product sold mostly through one US specialty pharmacy, competing DEB treatments approved in 2023 and 2025, pricing negotiations in Europe, and pipeline trials that have repeatedly taken longer than planned. A US Department of Justice inquiry into a Vyjuvek genetic-testing program is unresolved. More in the Long View →
What is Jeune Aesthetics?
A wholly owned Krystal subsidiary that is testing injections of the same type of gene-delivery vector for cosmetic uses, such as wrinkles on the upper chest. Krystal said in September 2026 that it had paused Jeune to focus on its rare-disease trials and was seeking a partner. Its products are investigational: none is approved, the data come from small company-run early trials, and long-term safety in healthy people is not yet established. More in the Long View →
Has Krystal diluted its shareholders?
Yes, heavily before Vyjuvek was approved: shares outstanding rose about 48% from the end of 2020 to the end of 2025, mainly from share sales in 2021–2023 to fund development. It has sold no shares for cash since 2023 and in November 2026 authorized up to $400 million of buybacks. More in the Long View →
What's coming up for Krystal Biotech's pipeline in the next 12 months?
Krystal expects interim KB111 results in Hailey-Hailey disease before the end of 2026; the last patient visit in its registrational KB803 eye study in February 2027, with top-line results shortly after; interim KB407 cystic fibrosis results in the first half of 2027; and to start registrational studies of KB407 and KB111 in 2027. It expects KB801 top-line results in 2027. As of Nov 2, 2026 More in the Long View →